Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer

被引：0
|
作者：
Andreas Teufel
Silke Steinmann
Jürgen Siebler
Christiane Zanke
Herbert Hohl
Bernd Adami
M Schroeder
O Klein
Thomas Höhler
Peter R Galle
Michael Heike
Markus Moehler
机构：
[1] Johannes Gutenberg University,Dept. of Internal Medicine I, Outpatient Unit for GI Cancer
[2] Hospital Bad Ems,undefined
[3] Outpatient Unit,undefined
[4] General practice,undefined
[5] General practice,undefined
[6] General practice,undefined
来源：
BMC Cancer | / 4卷
关键词：
irinotecan; 5-fluorouracil; safety; metastatic colorectal cancer; neoadjuvant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer
    Cunningham, D
    Falk, S
    Jackson, D
    BRITISH JOURNAL OF CANCER, 2002, 86 (11) : 1677 - 1683
  • [22] First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer
    Masi, G.
    Marcucci, L.
    Loupakis, F.
    Cerri, E.
    Barbara, C.
    Bursi, S.
    Allegrini, G.
    Brunetti, I. M.
    Murr, R.
    Ricci, S.
    Cupini, S.
    Andreuccetti, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2006, 17 (08) : 1249 - 1254
  • [23] Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
    Jeeyun Lee
    Kyung Hae Jung
    Young Suk Park
    Joong Bae Ahn
    Sang Jun Shin
    Seock-Ah Im
    Do Youn Oh
    Dong Bok Shin
    Tae Won Kim
    Namsu Lee
    Jae Ho Byun
    Yong Sang Hong
    Joon Oh Park
    Se Hoon Park
    Ho Yeong Lim
    Won Ki Kang
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 657 - 663
  • [24] Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
    Lee, Jeeyun
    Jung, Kyung Hae
    Park, Young Suk
    Ahn, Joong Bae
    Shin, Sang Jun
    Im, Seock-Ah
    Oh, Do Youn
    Shin, Dong Bok
    Kim, Tae Won
    Lee, Namsu
    Byun, Jae Ho
    Hong, Yong Sang
    Park, Joon Oh
    Park, Se Hoon
    Lim, Ho Yeong
    Kang, Won Ki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (04) : 657 - 663
  • [25] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer: Final results
    Kopetz, S.
    Glover, K.
    Eng, C.
    Wolff, R.
    Chang, D.
    Adinin, R.
    Morris, J.
    Abbruzzese, S.
    Hoff, P.
    ANNALS OF ONCOLOGY, 2007, 18 : VII80 - VII80
  • [26] Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer
    Mabro, M
    Louvet, C
    André, T
    Carola, E
    Gilles-Amar, V
    Artru, P
    Krulik, M
    de Gramont, A
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (03): : 254 - 258
  • [27] Oxaliplatin, 5-fluorouracil, and folinic acid as first-line treatment in metastatic or recurrent gastric cancer
    Kim, H.
    Yun, J.
    Kim, K.
    Kim, S.
    Lee, S.
    Bae, S.
    Lee, K.
    Hong, D.
    Park, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Phase I dose escalation and pharmacokinetics study of intravenous aflibercept plus irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) in patients with metastatic colorectal cancer
    Yamazaki, K.
    Yeshlno, T.
    Yamaguchi, K.
    Boku, N.
    Machlda, N.
    Onozawa, Y.
    Asayama, M.
    Doi, T.
    Ohtsu, A.
    Aoyama, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [29] Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study
    Ting Deng
    Le Zhang
    Xiao-jian Liu
    Jian-ming Xu
    Yu-xian Bai
    Yan Wang
    Yu Han
    Yu-hong Li
    Yi Ba
    Medical Oncology, 2013, 30
  • [30] Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study
    Deng, Ting
    Zhang, Le
    Liu, Xiao-jian
    Xu, Jian-ming
    Bai, Yu-xian
    Wang, Yan
    Han, Yu
    Li, Yu-hong
    Ba, Yi
    MEDICAL ONCOLOGY, 2013, 30 (04)
12345